Pиcк развития гиперплазии и рака предстательной железы при акромегалии
https://doi.org/10.14341/probl201056530-32
Аннотация
Список литературы
1. Дедов И.И., Молитвословова Н.А. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. М 2003;38.
2. Kronenberg H.M. Shlomo Melmed. Willams textbook of endocrinology. 2006; 3985.
3. Hankinson S.E., Willett W.C., Colditz G.A. et al. Circulating concentrations of Insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
4. Kurimoto M., Fukuda I., Hizuka N., Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Rev Endocr Metab Dis 2008;9:1: 1-58.
5. Orme S.M., McNally R.J.Q., Cartwright R.A., Belcheta P.E. for the United Kingdom Acromegaly Study Group. Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 1998;83:2730-2734.
6. Webb S.M., Casanueva F., Wass J.A.H. Oncological Complications of Excess GH in Acromegaly. Pituitary 2002;5:1:21-25.
7. Colao A., Marzullo P. Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects. J Clin Endocrinol Metab 1998;84:6:1986-1991.
8. Colao А., Marzullo P., Ferone D. Prostatic Hyperplasia: An Unknown Feature of Acromegaly. J Clin Endocrinol Metab 1998;83:7:2606-2607.
9. Cuhna G.R., Donjacour A.A., Cooke P.S. et al. The endocrinology and developmental biology of the prostate. Endocrin Rev 1987;8:338-362.
10. Wilson J.D. The pathogenesis of benign prostatic hyperplasia. Am J Med 1980;68:745-756.
11. Daughaday W.H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990;127:1:1-4.
12. Monti S., Di Silverio F., Lanzara S. et al. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: relationship with binding proteins 2 and 3 and androgens. Steroids 1998;63:362-366.
13. Chan J.M., Stampfer M.J., Giovannucci E. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566.
14. Ho P.G., Baxter R. Insulin-like growth factor binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997;46:333-342.
15. Mantzoros C.S., Tzonou A., Signorello L.B. et al. Insulin-like growth factor-I in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;77:1115-1118.
16. Grimberg A., Cohen P. Growth hormone and prostate cancer: guilty by association. J Endocrinol Inv 1999;22:5:Suppl:64-73.
17. Shim M., Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm Res 1999;51:Suppl 3:42-51.
18. Cohen P., Peehl D.M., Stamey T.A. et al. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993;76:1031-1035.
19. Kanety H., Madjar Y., Dagan Y. et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1998;77:229-233.
20. Rajaram S., Baylink D.J., Moan S. Insulin-like growth factor-binding proteins in serum and other bilogiocal fluids: regulation and function. Endocrin Rev 1997;18:801-831.
21. Colao A., Marzullo P., Spiezia S. Effect of Two Years of Growth Hormone and Insulin-Like Growth Factor-I Suppression on Prostate Diseases in Acromegalic Patients.
Рецензия
Для цитирования:
, , , , Pиcк развития гиперплазии и рака предстательной железы при акромегалии. Проблемы Эндокринологии. 2010;56(5):30-32. https://doi.org/10.14341/probl201056530-32
For citation:
Rozhivanov R.V., Fabrichnova A.A., Lepetukhin A.E., Dubskiĭ S.A., Kurbatov D.G. The risk of development of prostatic hyperplasia and prostate cancer in patients presenting with acromegalia. Problems of Endocrinology. 2010;56(5):30-32. https://doi.org/10.14341/probl201056530-32

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).